BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
10/25/2024 10:27:35 AM | Browse: 317 | Download: 760
Publication Name World Journal of Gastrointestinal Oncology
Manuscript ID 99661
Country China
ISSN 1948-5204 (online)
Open Access This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Copyright The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Gastroenterology & Hepatology
Manuscript Type Letter to the Editor
Article Title From biomarker discovery to combined therapies: Advancing hepatocellular carcinoma treatment strategies
Manuscript Source Invited Manuscript
All Author List Mo-Wei Kong, Yang Yu, Ying Wan, Yu Gao and Chun-Xiang Zhang
ORCID
Author(s) ORCID Number
Mo-Wei Kong http://orcid.org/0000-0002-1214-164X
Chun-Xiang Zhang http://orcid.org/0000-0001-8303-6495
Funding Agency and Grant Number
Funding Agency Grant Number
TNational Natural Science Foundation of China U23A20398
National Natural Science Foundation of China 82030007
Sichuan Science and Technology Program 2022YFS0578
Corresponding Author Chun-Xiang Zhang, MD, Professor, Department of Pharmacology and Rush University Cardiovascular Research Center, Rush University Medical Center, No. 25 Taiping Street, Luzhou 646000, Sichuan Province, China. zhangchx999@163.com
Key Words Hepatocellular carcinoma; Triple therapy; Transarterial chemoembolization; Protein tyrosine phosphatase non-receptor II
Core Tip This article review the integration of novel combined therapies and biomarker identification in hepatocellular carcinoma (HCC) management. The studies by Zhang et al and Li et al explore the efficaciousness of a triple therapy involving transarterial chemoembolization, tyrosine kinase inhibitors, and PD-1 inhibitors, and the prognostic value of protein tyrosine phosphatase non-receptor II (PTPN2), respectively. These investigations underscore the significance of PTPN2 as a potential therapeutic target and highlight the promise of synergistic treatment strategies in enhancing HCC patient outcomes.
Publish Date 2024-10-25 10:27
Citation

Kong MW, Yu Y, Wan Y, Gao Y, Zhang CX. From biomarker discovery to combined therapies: Advancing hepatocellular carcinoma treatment strategies. World J Gastrointest Oncol 2024; 16(11): 4518-4521

URL https://www.wjgnet.com/1948-5204/full/v16/i11/4518.htm
DOI https://dx.doi.org/10.4251/wjgo.v16.i11.4518
Full Article (PDF) WJGO-16-4518-with-cover.pdf